In an analysis of 23 CRC PDX models, Krumbach et al. formulated a “cetuximab response score” by assessing biomarkers such as epiregulin, amphiregulin, and levels of EGFR, MET, AKT, and HER3.66 This evidence concerns the gene EGFR and colorectal carcinoma.